Drug concentration asymmetry in tissues and plasma for small molecule-related therapeutic modalities

Donglu Zhang, Cornelis E.C.A. Hop, Gabriela Patilea-Vrana, Gautham Gampa, Herana Kamal Seneviratne, Jashvant D. Unadkat, Jane R. Kenny, Karthik Nagapudi, Li Di, Lian Zhou, Mark Zak, Matthew R. Wright, Namandje N Bumpus, Richard Zang, Xingrong Liu, Yurong Lai, S. Cyrus Khojasteh

Research output: Contribution to journalArticle

Abstract

The well accepted "free drug hypothesis" for small-molecule drugs assumes that only the free (unbound) drug concentration at the therapeutic target can elicit a pharmacologic effect. Unbound (free) drug concentrations in plasma are readily measurable and are often used as surrogates for the drug concentrations at the site of pharmacologic action in pharmacokinetic-pharmacodynamic analysis and clinical dose projection in drug discovery. Furthermore, for permeable compounds at pharmacokinetic steady state, the free drug concentration in tissue is likely a close approximation of that in plasma; however, several factors can create and maintain disequilibrium between the free drug concentration in plasma and tissue, leading to free drug concentration asymmetry. These factors include drug uptake and extrusion mechanisms involving the uptake and efflux drug transporters, intracellular biotransformation of prodrugs, membrane receptor-mediated uptake of antibody-drug conjugates, pH gradients, unique distribution properties (covalent binders, nanoparticles), and local drug delivery (e.g., inhalation). The impact of these factors on the free drug concentrations in tissues can be represented by Kp,uu, the ratio of free drug concentration between tissue and plasma at steady state. This review focuses on situations in which free drug concentrations in tissues may differ from those in plasma (e.g., Kp,uu > or <1) and discusses the limitations of the surrogate approach of using plasmafree drug concentration to predict free drug concentrations in tissue. This is an important consideration for novel therapeutic modalities since systemic exposure as a driver of pharmacologic effects may provide limited value in guiding compound optimization, selection, and advancement. Ultimately, a deeper understanding of the relationship between free drug concentrations in plasma and tissues is needed.

Original languageEnglish (US)
Pages (from-to)1122-1135
Number of pages14
JournalDrug Metabolism and Disposition
Volume47
Issue number10
DOIs
StatePublished - Jan 1 2019

Fingerprint

Pharmaceutical Preparations
Therapeutics
Pharmacokinetics
Pharmacologic Actions
Proton-Motive Force
Prodrugs
Drug Discovery
Biotransformation
Nanoparticles
Inhalation
Membranes
Antibodies

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Zhang, D., Hop, C. E. C. A., Patilea-Vrana, G., Gampa, G., Seneviratne, H. K., Unadkat, J. D., ... Cyrus Khojasteh, S. (2019). Drug concentration asymmetry in tissues and plasma for small molecule-related therapeutic modalities. Drug Metabolism and Disposition, 47(10), 1122-1135. https://doi.org/10.1124/dmd.119.086744

Drug concentration asymmetry in tissues and plasma for small molecule-related therapeutic modalities. / Zhang, Donglu; Hop, Cornelis E.C.A.; Patilea-Vrana, Gabriela; Gampa, Gautham; Seneviratne, Herana Kamal; Unadkat, Jashvant D.; Kenny, Jane R.; Nagapudi, Karthik; Di, Li; Zhou, Lian; Zak, Mark; Wright, Matthew R.; Bumpus, Namandje N; Zang, Richard; Liu, Xingrong; Lai, Yurong; Cyrus Khojasteh, S.

In: Drug Metabolism and Disposition, Vol. 47, No. 10, 01.01.2019, p. 1122-1135.

Research output: Contribution to journalArticle

Zhang, D, Hop, CECA, Patilea-Vrana, G, Gampa, G, Seneviratne, HK, Unadkat, JD, Kenny, JR, Nagapudi, K, Di, L, Zhou, L, Zak, M, Wright, MR, Bumpus, NN, Zang, R, Liu, X, Lai, Y & Cyrus Khojasteh, S 2019, 'Drug concentration asymmetry in tissues and plasma for small molecule-related therapeutic modalities', Drug Metabolism and Disposition, vol. 47, no. 10, pp. 1122-1135. https://doi.org/10.1124/dmd.119.086744
Zhang, Donglu ; Hop, Cornelis E.C.A. ; Patilea-Vrana, Gabriela ; Gampa, Gautham ; Seneviratne, Herana Kamal ; Unadkat, Jashvant D. ; Kenny, Jane R. ; Nagapudi, Karthik ; Di, Li ; Zhou, Lian ; Zak, Mark ; Wright, Matthew R. ; Bumpus, Namandje N ; Zang, Richard ; Liu, Xingrong ; Lai, Yurong ; Cyrus Khojasteh, S. / Drug concentration asymmetry in tissues and plasma for small molecule-related therapeutic modalities. In: Drug Metabolism and Disposition. 2019 ; Vol. 47, No. 10. pp. 1122-1135.
@article{23706e972a0b4b799addf7a43ad9ab99,
title = "Drug concentration asymmetry in tissues and plasma for small molecule-related therapeutic modalities",
abstract = "The well accepted {"}free drug hypothesis{"} for small-molecule drugs assumes that only the free (unbound) drug concentration at the therapeutic target can elicit a pharmacologic effect. Unbound (free) drug concentrations in plasma are readily measurable and are often used as surrogates for the drug concentrations at the site of pharmacologic action in pharmacokinetic-pharmacodynamic analysis and clinical dose projection in drug discovery. Furthermore, for permeable compounds at pharmacokinetic steady state, the free drug concentration in tissue is likely a close approximation of that in plasma; however, several factors can create and maintain disequilibrium between the free drug concentration in plasma and tissue, leading to free drug concentration asymmetry. These factors include drug uptake and extrusion mechanisms involving the uptake and efflux drug transporters, intracellular biotransformation of prodrugs, membrane receptor-mediated uptake of antibody-drug conjugates, pH gradients, unique distribution properties (covalent binders, nanoparticles), and local drug delivery (e.g., inhalation). The impact of these factors on the free drug concentrations in tissues can be represented by Kp,uu, the ratio of free drug concentration between tissue and plasma at steady state. This review focuses on situations in which free drug concentrations in tissues may differ from those in plasma (e.g., Kp,uu > or <1) and discusses the limitations of the surrogate approach of using plasmafree drug concentration to predict free drug concentrations in tissue. This is an important consideration for novel therapeutic modalities since systemic exposure as a driver of pharmacologic effects may provide limited value in guiding compound optimization, selection, and advancement. Ultimately, a deeper understanding of the relationship between free drug concentrations in plasma and tissues is needed.",
author = "Donglu Zhang and Hop, {Cornelis E.C.A.} and Gabriela Patilea-Vrana and Gautham Gampa and Seneviratne, {Herana Kamal} and Unadkat, {Jashvant D.} and Kenny, {Jane R.} and Karthik Nagapudi and Li Di and Lian Zhou and Mark Zak and Wright, {Matthew R.} and Bumpus, {Namandje N} and Richard Zang and Xingrong Liu and Yurong Lai and {Cyrus Khojasteh}, S.",
year = "2019",
month = "1",
day = "1",
doi = "10.1124/dmd.119.086744",
language = "English (US)",
volume = "47",
pages = "1122--1135",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "10",

}

TY - JOUR

T1 - Drug concentration asymmetry in tissues and plasma for small molecule-related therapeutic modalities

AU - Zhang, Donglu

AU - Hop, Cornelis E.C.A.

AU - Patilea-Vrana, Gabriela

AU - Gampa, Gautham

AU - Seneviratne, Herana Kamal

AU - Unadkat, Jashvant D.

AU - Kenny, Jane R.

AU - Nagapudi, Karthik

AU - Di, Li

AU - Zhou, Lian

AU - Zak, Mark

AU - Wright, Matthew R.

AU - Bumpus, Namandje N

AU - Zang, Richard

AU - Liu, Xingrong

AU - Lai, Yurong

AU - Cyrus Khojasteh, S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The well accepted "free drug hypothesis" for small-molecule drugs assumes that only the free (unbound) drug concentration at the therapeutic target can elicit a pharmacologic effect. Unbound (free) drug concentrations in plasma are readily measurable and are often used as surrogates for the drug concentrations at the site of pharmacologic action in pharmacokinetic-pharmacodynamic analysis and clinical dose projection in drug discovery. Furthermore, for permeable compounds at pharmacokinetic steady state, the free drug concentration in tissue is likely a close approximation of that in plasma; however, several factors can create and maintain disequilibrium between the free drug concentration in plasma and tissue, leading to free drug concentration asymmetry. These factors include drug uptake and extrusion mechanisms involving the uptake and efflux drug transporters, intracellular biotransformation of prodrugs, membrane receptor-mediated uptake of antibody-drug conjugates, pH gradients, unique distribution properties (covalent binders, nanoparticles), and local drug delivery (e.g., inhalation). The impact of these factors on the free drug concentrations in tissues can be represented by Kp,uu, the ratio of free drug concentration between tissue and plasma at steady state. This review focuses on situations in which free drug concentrations in tissues may differ from those in plasma (e.g., Kp,uu > or <1) and discusses the limitations of the surrogate approach of using plasmafree drug concentration to predict free drug concentrations in tissue. This is an important consideration for novel therapeutic modalities since systemic exposure as a driver of pharmacologic effects may provide limited value in guiding compound optimization, selection, and advancement. Ultimately, a deeper understanding of the relationship between free drug concentrations in plasma and tissues is needed.

AB - The well accepted "free drug hypothesis" for small-molecule drugs assumes that only the free (unbound) drug concentration at the therapeutic target can elicit a pharmacologic effect. Unbound (free) drug concentrations in plasma are readily measurable and are often used as surrogates for the drug concentrations at the site of pharmacologic action in pharmacokinetic-pharmacodynamic analysis and clinical dose projection in drug discovery. Furthermore, for permeable compounds at pharmacokinetic steady state, the free drug concentration in tissue is likely a close approximation of that in plasma; however, several factors can create and maintain disequilibrium between the free drug concentration in plasma and tissue, leading to free drug concentration asymmetry. These factors include drug uptake and extrusion mechanisms involving the uptake and efflux drug transporters, intracellular biotransformation of prodrugs, membrane receptor-mediated uptake of antibody-drug conjugates, pH gradients, unique distribution properties (covalent binders, nanoparticles), and local drug delivery (e.g., inhalation). The impact of these factors on the free drug concentrations in tissues can be represented by Kp,uu, the ratio of free drug concentration between tissue and plasma at steady state. This review focuses on situations in which free drug concentrations in tissues may differ from those in plasma (e.g., Kp,uu > or <1) and discusses the limitations of the surrogate approach of using plasmafree drug concentration to predict free drug concentrations in tissue. This is an important consideration for novel therapeutic modalities since systemic exposure as a driver of pharmacologic effects may provide limited value in guiding compound optimization, selection, and advancement. Ultimately, a deeper understanding of the relationship between free drug concentrations in plasma and tissues is needed.

UR - http://www.scopus.com/inward/record.url?scp=85072508772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072508772&partnerID=8YFLogxK

U2 - 10.1124/dmd.119.086744

DO - 10.1124/dmd.119.086744

M3 - Article

VL - 47

SP - 1122

EP - 1135

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 10

ER -